Sept 27 (Reuters) - Pfizer Inc said on Monday it has started a mid-to-late-stage study testing its investigational oral antiviral drug, to be co-administered with HIV drug ritonavir, for the prevention of COVID-19 infection. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri)
Stock market news
- Stock
- Stock market news
- Economy
- Pfizer begins study for COVID-19 antiviral drug